Lisa A. Carey, MD, ScM, FASCO (IMAGE)

University of North Carolina Health Care

Lisa A. Carey, MD, ScM, FASCO

Caption

“Despite progress in treating breast cancer during the past 30 years, we still lack curative therapies for metastatic disease. EVOLVE takes a different approach to clinical research by using real-time biomarker data to adapt treatment as a tumor changes," said Lisa Carey, MD, ScM, FASCO, the study’s lead investigator and the L. Richardson and Marilyn Jacobs Preyer Distinguished Professor for Breast Cancer Research at UNC School of Medicine and the deputy director of clinical sciences at UNC Lineberger.

Credit

UNC Lineberger Comprehensive Cancer Center

Usage Restrictions

None

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.